Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Perspective Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Johan (Thijs) Spoor, Chief Executive Officer of the Company, Jonathan Hunt, Chief Financial Officer, and Mark J. Austin, Vice President of Finance and Corporate Controller, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:
Dated: August 13, 2024
/s/ Johan (Thijs) Spoor | |
Johan (Thijs) Spoor | |
Chief Executive Officer | |
/s/ Jonathan Hunt | |
Jonathan Hunt | |
Chief Financial Officer | |
/s/ Mark J. Austin | |
Mark J. Austin | |
Vice President of Finance and Corporate Controller |